Idorsia Ltd
Registry to Collect Information on Pregnancy, Neonatal, and Infant Outcomes in Pregnant Women Exposed to QUVIVIQ®
- Conditions
- Interventions
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 785
- Registration Number
- NCT06498128
- Locations
- 🇺🇸
IQVIA US Office, Durham, North Carolina, United States
🇨🇦Jodha Tishon, Toronto, Ontario, Canada
🇫🇷Hôpital Gui de Chauliac, Montpellier, France
Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 680
- Registration Number
- NCT06475742
- Locations
- 🇨🇿
iMedica s.r.o., Brno, Czechia
🇨🇿Institute of Rheumatology Prague, Prague, Czechia
🇩🇪Universitatsklinikum Leipzig, Leipzig, Germany
Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant)
- Conditions
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 2095
- Registration Number
- NCT06393504
- Locations
- 🇺🇸
Carelon Research, Wilmington, Delaware, United States
A Phase 1 Trial to Investigate the Biological Equivalence of 5 × 10 mg Tablets and 2 × 25 mg Tablets of Daridorexant in Healthy Male and Female Japanese Participants
- First Posted Date
- 2023-05-26
- Last Posted Date
- 2023-08-16
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT05877222
- Locations
- 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
A Study of the Effect of Daridorexant on Nighttime Body Posture, the Noise Level Required to Wake up, and the Ability to Remember Words Previously Presented
- Conditions
- Interventions
- First Posted Date
- 2023-01-27
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05702177
- Locations
- 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands
A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT05672576
- Locations
- 🇺🇸
Tucson Clinical Research Institute, LLC, Tucson, Arizona, United States
🇺🇸UCSD Perlman Medical Offices, La Jolla, California, United States
🇺🇸BioSolutions Clinical Research Center, Poway, California, United States
A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 420
- Registration Number
- NCT05648500
- Locations
- 🇷🇴
Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania
🇷🇴SC Sana Monitoring SRL, Bucuresti, Romania
🇷🇴Delta Health Care SRL, Bucuresti, Romania
A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women
- First Posted Date
- 2022-11-30
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT05632393
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc., Madison, Wisconsin, United States
A Post Approval Study to Investigate the Efficacy of Daridorexant in Subjects With Insomnia and Comorbid Nocturia
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2024-05-22
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05597020
- Locations
- 🇺🇸
Accellacare Research of Cary, Cary, North Carolina, United States
🇺🇸Quantum Clinical Trials, Miami Beach, Florida, United States
🇺🇸Clinical Research Center of Florida, Pompano Beach, Florida, United States
A Study to Investigate the Effect of Itraconazole on the Way the Body Absorbs, Distributes, and Gets Rid of ACT-1004-1239 Given as a Single Dose of 10 mg to Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Idorsia Pharmaceuticals Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT05549531
- Locations
- 🇵🇹
BlueClinical Phase 1, Porto, Portugal